GlassScriptPhysician profile
Keith Doubet
NPI 1225735533
$674.57
in general payments reported to CMS, 2019-2025
12 companies · $563 in 2025
The $563 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $111 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $176.43 | 2025 | Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $111.27 | 2023 | Camzyos |
| Gilead Sciences, INC. | $67.89 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $59.84 | 2025 | Farxiga |
| Lilly USA, LLC | $59.01 | 2025 | Kisunla, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.81 | 2025 | Caplyta |
| Corcept Therapeutics | $44.19 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $34.59 | 2025 | Rexulti |
| Vertex Pharmaceuticals Incorporated | $19.07 | 2025 | |
| Amgen INC. | $18.30 | 2025 | Evenity |
| Kowa Pharmaceuticals America, INC. | $16.93 | 2025 | Zoryve |
| Glaxosmithkline, LLC. | $16.24 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Doubet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.